Search Results 721-730 of 3875 for 搜索留痕收录规则咨询邮箱：lgooxc@hotmail.com

1. Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma - Mayo Clinic

   Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

2. DeLisa Fairweather, Ph.D. - Mayo Clinic Faculty Profiles

   SUMMARY. DeLisa Fairweather, Ph.D., is director of translational research for the Department of Cardiovascular Diseases at Mayo Clinic's Florida campus.

3. Ulrich Specks, M.D. - Mayo Clinic Faculty Profiles

   Mayo Clinic researcher Ulrich Specks, M.D., focuses on antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

4. Pulmonary Hypertension Association Registry - Mayo Clinic

   About this study. The PHAR is a multicenter, prospective registry of newly evaluated patients at PHCCs in the United States who have either PAH or CTEPH.

5. Faculty and Staff - Lymphoma Epidemiology Laboratory - Mayo Clinic Research

   Dr. Cerhan's team in the Lymphoma Epidemiology Lab at Mayo Clinic has expertise in cancer epidemiology, hematology, immunology, laboratory medicine and ...

6. A Study Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women with Type 1 Von Willebrand Disease - Mayo Clinic

   The purpose of this study is to compare recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to minimize menorrhagia in women with Type 1 Von ...

7. A Study to Evaluate ALZT-OP1a in Subjects with Mild-to-Moderate Amyotrophic Lateral Sclerosis - Mayo Clinic

   About this study. The purposes of this study are to measure the impact of two doses of ALZT-OP1a (cromolyn) on neuro-inflammation by measuring plasma ...

8. Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF - Mayo Clinic

   Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

9. Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma - Mayo Clinic

   Vorasidenib in combination with pembrolizumab in participants with recurrent or progressive isocitrate dehydrogenase-1 (IDH-1) mutant Glioma. Participation ...

10. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors - Mayo Clinic

    About this study. This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyl transferase inhibitor (FTI), ...